Table 2.
Baseline plasma biomarkers and univariate associations for patients with and without infarct growth
| All patients (n=220) | No infarct growth (n=50) | Infarct growth (n=170) | P-value | |
|---|---|---|---|---|
| F2-isoP, pg/mL | 52.5 (34.3–73.1) | 42.0 (27.0–61.8) | 56.2 (36.4–75.3) | 0.009 |
| ORACTOTAL, μmol TE/L | 18040.5 (13516.1–24428.0) | 15050.4 (12804.0–24752.1) | 18126.9 (14288.3–24314.4) | 0.38 |
| ORACPCA, μmol TE/L | 1546.6 (1193.0–2100.9) | 1564.5 (1240.0–2436.0) | 1530.7 (1182.9–2029.2) | 0.37 |
| 8-OHdG, ng/mL | 4.9 (2.6–9.6) | 3.4 (2.0–8.1) | 5.6 (2.7–9.8) | 0.18 |
| 8-OHdG_cr, ng/mL | 11.8 (7.0–21.6) | 13.5 (6.7–27.9) | 11.6 (7.1–21.6) | 0.73 |
| MMP-2, ng/mL | 302.3 (239.9–386.3) | 287.4 (238.0–387.7) | 313.6 (239.4–386.4) | 0.62 |
| MMP-9, ng/mL | 179.1 (97.6–318.6) | 165.3 (86.3–331.0) | 181.8 (100.2–319.2) | 0.65 |
| hs-CRP, mg/L | 3.6 (1.7–7.9) | 3.8 (1.7–9.3) | 3.5 (1.7–7.7) | 0.93 |
Values are medians (interquartile ranges, IQR).
F2-isoP=F2-isoprostane; hs-CRP=high sensitivity C Reactive Protein; μmol TE/L=micromoles of Trolox equivalents per liter; MMP-2=metalloproteinase 2; MMP-9=metalloproteinase 9; ng/mL=nanograms per millilitre; 8-OHdg=8-hydro-2′-deoxyguoanosine; 8-OHdg_cr=8-hydro-2′-deoxyguoanosine adjusted by creatinine (cr) levels; ORACPCA =Oxygen Radical Absorbance Capcity (PCA perchloric acid); pg/mL=picograms per milliliter.